Before 1994, most developing countries did not grant product patents on pharmaceutical compounds. India only allowed process patents — meaning domestic manufacturers could reverse-engineer the active ingredients of branded medicines using different chemical processes and sell the resulting generics at a fraction of the originator price. Brazil did the same. So did many African countries. The result was a pharmaceutical market in which generic competition constrained the price of essential medicines. The TRIPS Agreement changed this. Prior to TRIPS, many countries excluded pharmaceutical products from patentability in order to ensure drug prices were affordable. India and Brazil had previously only allowed for process patents, not product patents. This permitted domestic generic pharmaceutical companies to reverse-engineer and produce bioequivalent drugs. Under a TRIPS-compliant patent regime, WTO member states are required to guarantee product patents and exclusive marketing rights to innovators. Former World Bank Chief Economist Joseph Stiglitz described the TRIPS Agreement as "a death warrant for thousands of people in the poorest countries of the world." The evidence this article examines is whether that characterisation holds thirty years on.

The observable contradiction has two faces. The first is pharmaceutical. When a patent holder can exclude others from producing a medicine, it frequently charges monopoly prices. Its profit-maximising strategy in developing countries is typically to sell medicines at high prices to the rich even if that price excludes purchase by or for the vast majority of a country's population. The pharmaceutical market is not like the shipping market or the currency market in its directness. The person who cannot afford a patented antiretroviral in Nairobi or an insulin analogue in Lagos is not an abstraction. They are the direct consequence of a pricing decision made by a company whose intellectual property rights are enforced by the same WTO legal framework that enforces the trade rules the Global South accepted in exchange for market access in 1994.

The second face is agricultural. TRIPS requires all WTO members to adopt either patent protection or an effective sui generis system for new plant varieties. By joining the Union for the Protection of New Varieties of Plants — UPOV — countries give up their right to develop sui generis legislation and instead must harmonise their national policy with UPOV dictates. UPOV 91 prohibits even small-scale farmers from saving or sharing protected seeds. The smallholder farmer who has grown a particular variety, selected seed from the best plants, and replanted the following season — the most ancient and universal practice of agriculture — is, under UPOV 91, potentially liable to a seed company for doing so with a protected variety. The intellectual property framework designed to incentivise plant breeders to develop new varieties simultaneously criminalises the seed-saving practices that have sustained agricultural communities for ten thousand years.

The first constraint is the TRIPS-plus architecture. The TRIPS Agreement sets minimum standards. Bilateral and regional trade agreements between developed and developing countries have systematically added additional protections beyond TRIPS minimums — data exclusivity, patent term extensions, restrictions on compulsory licensing procedures — that further limit the space for generic competition. A 2019 study estimated that TRIPS-plus provisions cost lower and middle income countries $2.3 billion a year in lost savings from generic competition. These provisions are frequently negotiated in secret. Low-income countries, desperate for trade deals, agree to them. Then they're stuck. The WTO has found that 86 per cent of its 164 members have added these extra restrictions. The minimum standard established in 1994 was insufficient. The subsequent thirty years of bilateral trade negotiation have made it more restrictive, not less.

The second constraint is the practical barrier to using TRIPS flexibilities. The Doha Declaration of 2001 reaffirmed the right of WTO members to use compulsory licensing to override patents for public health purposes. The right exists in law. In practice, barriers to the effective use of TRIPS flexibilities include corporate lobbying, trade threats, technical capacity gaps, and the complexity of the legal procedures required to issue a compulsory licence in compliance with TRIPS. The evidence from the 2001-2024 period shows 149 compulsory licensing instances — 61 per cent of which were actually executed. For the world's least-developed countries, a specific pharmaceutical patent waiver running until January 2033 provides additional space. For the middle-income countries where the majority of the Global South's population lives, the constraint is real: the legal right exists, but exercising it requires navigating a procedure that pharmaceutical companies and their home governments — the United States and the European Union primarily — actively contest.

The third constraint is seed market concentration. A decade after the passage of the US Plant Variety Protection Act of 1970, five companies — all with less than ten years' work in plant breeding — controlled almost one third of the issued rights for American agricultural varieties. The consolidation of the seed industry has continued since. By 2024, a small number of multinational corporations — BASF, Bayer, ChemChina/Syngenta, Corteva, and Limagrain — dominate the global commercial seed market. The intellectual property protections that TRIPS requires for plant varieties create financial returns on research and development that favour large corporations with scale, capital, and global patent portfolio management capacity. The smallholder farmer in Burkina Faso or Malawi, whose agricultural knowledge and seed selection practices have produced the genetic diversity that commercial plant breeders' research relies upon, receives no royalty from the varieties derived from that diversity. The value flows in one direction: from traditional farming communities to commercial breeders, encoded as intellectual property, and back to the market as a patented seed the original knowledge-holders must now pay to use.

The Doha Declaration of 2001 was the first major correction. Adopted at the WTO ministerial conference in Qatar — brought about by the HIV/AIDS crisis in Africa, which had made the consequences of TRIPS pharmaceutical patent protection literally visible in the form of preventable deaths at a scale that political leaders could not ignore — it reaffirmed that WTO members have the right to use TRIPS flexibilities to protect public health, and that the agreement should be interpreted in a manner supportive of that right. The Doha Declaration produced real results: compulsory licensing contributed to a 92 per cent drop in the price of first-line HIV medications in low and middle income countries between 2000 and 2020, according to UNAIDS. Generic competition, enabled by the legal cover of the Doha Declaration, saved millions of lives.

The June 2022 COVID-19 TRIPS waiver was the second major correction. The WTO's June 2022 agreement temporarily waived certain patent protections for COVID-19 vaccines until 2027. Though only 12 facilities in 8 countries have started production under this waiver, it signals a shift toward broader emergency powers. The waiver was a genuine achievement — it required two years of negotiation and the active opposition of the pharmaceutical industry and its home governments. But its scope reveals the limits of the correction: vaccines only, not diagnostics, not treatments, and not future pandemics. A waiver that covers the specific product category where the originator companies had already achieved extraordinary profits — having received substantial public research funding, advance purchase commitments, and liability indemnification — while excluding the broader category of pandemic health technologies, is a correction shaped as much by what pharmaceutical companies would accept as by what global public health required.

In September 2024, the UN held a global meeting on pandemic preparedness. Its final statement called for "reform of the TRIPS Agreement to ensure timely access to health technologies during health emergencies." That is the first time a global body has openly stated that TRIPS is broken. The statement is significant as institutional acknowledgement. It has not yet produced reform. The pharmaceutical industry still spends billions lobbying against change. The United States and the European Union continue to block broader waivers.

The evidence suggests that TRIPS is the clearest case in this edition of an extraction mechanism that is also a legal architecture — one in which the extraction is not merely permitted by the rules but required by them. The shipping oligopoly's pricing power derives from market concentration. The dollar's reserve status derives from historical institutional arrangements. TRIPS is different: it is a treaty obligation that WTO member states are legally required to implement, enforced through a dispute settlement mechanism with real consequences for non-compliance. The Global South did not negotiate TRIPS from a position of strength. It was negotiated in the Uruguay Round alongside the market access concessions — in textiles, agriculture, and services — that developing countries wanted. The pharmaceutical patent protections were the price of those concessions. Whether the concessions received were worth the price paid is a question that three decades of evidence has answered in the negative for the populations who cannot afford the medicines the patents protect.

The correction available within the system — compulsory licensing — works when it is used. The 92 per cent reduction in HIV drug prices in LMICs between 2000 and 2020 is the most significant public health outcome produced by any trade policy flexibility in the post-TRIPS era. It was achieved despite pharmaceutical industry opposition, bilateral trade pressure, and the complexity of the legal procedure. The barrier to using it is not legal impossibility but institutional courage, technical capacity, and resistance to pressure from countries whose pharmaceutical industries benefit from patent protection being maintained. Most developing country governments lack the institutional capacity, the legal expertise, and the trade leverage to sustain that resistance when the United States or the European Union applies bilateral pressure in response to a compulsory licence issuance.